Clinical trial
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With…
NCT00384111 · Spectrum Pharmaceuticals, Inc, Industry · Terminated
Key facts
| NCT number | NCT00384111 |
|---|---|
| Title | Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) |
| Official title | A Phase 3 Open Label Multicenter, Randomized Study to Compare the Efficacy and Safety of the Zevalin (Ibritumomab Tiuxetan) Therapeutic Regimen Following Cyclophosphamide, Vincristine, Prednisone, and Rituximab (R-CVP) With R-CVP Alone in High-Risk Subjects With Previously Untreated CD20-Positive… |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Collaborators | CTI BioPharma Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Follicular Lymphoma, Lymphoma, Follicular |
| Intervention type | Drug |
| Interventions | Zevalin Therapeutic Regimen, R-CVP |
| Enrollment | 26 |
| Start date | Oct 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Oct 5, 2006 |
| Last update posted | Jan 14, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: